MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

Strona główna・Stock List・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Closed

SectorHealthcare

22.28 -3.92

Buy Sell

Overview

Share price change

24h

Current

Min

22.02

Max

23.22

Key metrics
By Trading Economics
Income	675K 53M
Sales	1.8M 148M
P/E Sector Avg	13.269 90.831
Profit margin	35.57
Employees	181
EBITDA	1.7M 80M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+46.43% upside

Dividends
By Dow Jones
Next Earnings	25 lut 2026

Market Stats
By TradingEconomics
Market Cap	230M 2.9B
Previous open	26.2
Previous close	22.28

News Sentiment

By Acuity

50%

183 / 361 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

N/A / 24.28 Support & Resistance

Catalyst Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 sty 2026, 19:05 UTC

Major Market Movers

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13 sty 2026, 23:41 UTC

Market Talk

Nikkei May Rise on Japan Election Hopes -- Market Talk

13 sty 2026, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

13 sty 2026, 23:33 UTC

Market Talk

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13 sty 2026, 23:13 UTC

Acquisitions, Mergers, Takeovers

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13 sty 2026, 23:10 UTC

Acquisitions, Mergers, Takeovers

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13 sty 2026, 23:03 UTC

Market Talk

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13 sty 2026, 21:50 UTC

Acquisitions, Mergers, Takeovers

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13 sty 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

13 sty 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13 sty 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13 sty 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13 sty 2026, 21:15 UTC

Acquisitions, Mergers, Takeovers

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13 sty 2026, 21:08 UTC

Acquisitions, Mergers, Takeovers

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13 sty 2026, 20:39 UTC

Market Talk

Silver Settles at Another New High -- Market Talk

13 sty 2026, 20:21 UTC

Market Talk

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13 sty 2026, 20:17 UTC

Market Talk

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13 sty 2026, 19:08 UTC

Acquisitions, Mergers, Takeovers

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13 sty 2026, 19:03 UTC

Earnings

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13 sty 2026, 18:50 UTC

Earnings

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13 sty 2026, 17:54 UTC

Market Talk

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13 sty 2026, 17:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

13 sty 2026, 17:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13 sty 2026, 17:49 UTC

Market Talk

Analysts Call For Potential Record Ethanol Output -- Market Talk

13 sty 2026, 17:38 UTC

Market Talk

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13 sty 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

13 sty 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

13 sty 2026, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

13 sty 2026, 17:19 UTC

Market Talk

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13 sty 2026, 17:15 UTC

Market Talk

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Peer Comparison

Price change

Catalyst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

46.43% upside

12 Months Forecast

Average 34 USD 46.43%

High 35 USD

Low 33 USD

Based on 5 Wall Street analysts offering 12 month price targets forCatalyst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Catalyst Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 24.28Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

183 / 361 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.